These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 8973989)
1. Metabolic profiles of minimally absorbed orlistat in obese/overweight volunteers. Zhi J; Melia AT; Funk C; Viger-Chougnet A; Hopfgartner G; Lausecker B; Wang K; Fulton JS; Gabriel L; Mulligan TE J Clin Pharmacol; 1996 Nov; 36(11):1006-11. PubMed ID: 8973989 [TBL] [Abstract][Full Text] [Related]
2. The effect of orlistat, an inhibitor of dietary fat absorption, on the pharmacokinetics of beta-carotene in healthy volunteers. Zhi J; Melia AT; Koss-Twardy SG; Arora S; Patel IH J Clin Pharmacol; 1996 Feb; 36(2):152-9. PubMed ID: 8852391 [TBL] [Abstract][Full Text] [Related]
3. Long-term systemic exposure of orlistat, a lipase inhibitor, and its metabolites in obese patients. Zhi J; Mulligan TE; Hauptman JB J Clin Pharmacol; 1999 Jan; 39(1):41-6. PubMed ID: 9987699 [TBL] [Abstract][Full Text] [Related]
4. The interaction of the lipase inhibitor orlistat with ethanol in healthy volunteers. Melia AT; Zhi J; Zelasko R; Hartmann D; Güzelhan C; Guerciolini R; Odink J Eur J Clin Pharmacol; 1998; 54(9-10):773-7. PubMed ID: 9923583 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of 14C-radioactivity after oral intake of a single dose of 14C-labeled fampridine (4-aminopyridine) in healthy volunteers. Blight AR; Henney HR Clin Ther; 2009 Feb; 31(2):328-35. PubMed ID: 19302905 [TBL] [Abstract][Full Text] [Related]
6. Mass balance study of [14C] rabeprazole following oral administration in healthy subjects. Setoyama T; Drijfhout WJ; van de Merbel NC; Humphries TJ; Hasegawa J Int J Clin Pharmacol Ther; 2006 Nov; 44(11):557-65. PubMed ID: 17176622 [TBL] [Abstract][Full Text] [Related]
7. Effects of orlistat, a lipase inhibitor, on the pharmacokinetics of three highly lipophilic drugs (amiodarone, fluoxetine, and simvastatin) in healthy volunteers. Zhi J; Moore R; Kanitra L; Mulligan TE J Clin Pharmacol; 2003 Apr; 43(4):428-35. PubMed ID: 12723464 [TBL] [Abstract][Full Text] [Related]
8. A phase I, open-label, single-dose, mass balance study of 14C-labeled abiraterone acetate in healthy male subjects. Acharya M; Gonzalez M; Mannens G; De Vries R; Lopez C; Griffin T; Tran N Xenobiotica; 2013 Apr; 43(4):379-89. PubMed ID: 23020788 [TBL] [Abstract][Full Text] [Related]
9. Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers. Zhi J; Melia AT; Eggers H; Joly R; Patel IH J Clin Pharmacol; 1995 Nov; 35(11):1103-8. PubMed ID: 8626884 [TBL] [Abstract][Full Text] [Related]
10. The influence of reduced dietary fat absorption induced by orlistat on the pharmacokinetics of digoxin in healthy volunteers. Melia AT; Zhi J; Koss-Twardy SG; Min BH; Smith BL; Freundlich NL; Arora S; Passe SM J Clin Pharmacol; 1995 Aug; 35(8):840-3. PubMed ID: 8522642 [TBL] [Abstract][Full Text] [Related]
11. The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers. Melia AT; Koss-Twardy SG; Zhi J J Clin Pharmacol; 1996 Jul; 36(7):647-53. PubMed ID: 8844448 [TBL] [Abstract][Full Text] [Related]
12. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Zhi J; Melia AT; Guerciolini R; Chung J; Kinberg J; Hauptman JB; Patel IH Clin Pharmacol Ther; 1994 Jul; 56(1):82-5. PubMed ID: 8033498 [TBL] [Abstract][Full Text] [Related]
13. Orlistat maintains biliary lipid composition and hepatobiliary function in obese subjects undergoing moderate weight loss. Trouillot TE; Pace DG; McKinley C; Cockey L; Zhi J; Häeussler J; Guerciolini R; Showalter R; Everson GT Am J Gastroenterol; 2001 Jun; 96(6):1888-94. PubMed ID: 11421247 [TBL] [Abstract][Full Text] [Related]
14. The effect of orlistat on the pharmacokinetics of phenytoin in healthy volunteers. Melia AT; Mulligan TE; Zhi J J Clin Pharmacol; 1996 Jul; 36(7):654-8. PubMed ID: 8844449 [TBL] [Abstract][Full Text] [Related]
15. The influence of orlistat on the pharmacokinetics and pharmacodynamics of glyburide in healthy volunteers. Zhi J; Melia AT; Koss-Twardy SG; Min B; Guerciolini R; Freundlich NL; Milla G; Patel IH J Clin Pharmacol; 1995 May; 35(5):521-5. PubMed ID: 7657854 [TBL] [Abstract][Full Text] [Related]
16. Disposition and metabolism of finasteride in dogs. Carlin JR; Christofalo P; Arison BH; Ellsworth RE; Rosegay A; Miller RR; Chiu SH; VandenHeuvel WJ Drug Metab Dispos; 1997 Jan; 25(1):100-9. PubMed ID: 9010636 [TBL] [Abstract][Full Text] [Related]
17. Diagnosing malabsorption with systemic lipid profiling: pharmacokinetics of pentadecanoic acid and triheptadecanoic acid following oral administration in healthy subjects and subjects with cystic fibrosis. Stallings VA; Mondick JT; Schall JI; Barrett JS; Wilson M; Mascarenhas MR Int J Clin Pharmacol Ther; 2013 Apr; 51(4):263-73. PubMed ID: 23357842 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic evaluation of the possible interaction between selected concomitant medications and orlistat at steady state in healthy subjects. Zhi J; Moore R; Kanitra L; Mulligan TE J Clin Pharmacol; 2002 Sep; 42(9):1011-9. PubMed ID: 12211217 [TBL] [Abstract][Full Text] [Related]
19. [Pharmacological therapy of obesity]. Pagotto U; Vanuzzo D; Vicennati V; Pasquali R G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755 [TBL] [Abstract][Full Text] [Related]
20. The disposition of [14C]-labelled benazepril HCl in normal adult volunteers after single and repeated oral dose. Waldmeier F; Kaiser G; Ackermann R; Faigle JW; Wagner J; Barner A; Lasseter KC Xenobiotica; 1991 Feb; 21(2):251-61. PubMed ID: 2058180 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]